AU2022376557A1 - Methods for treating cardiovascular conditions and methods of increasing the efficiency of cardiac metabolism - Google Patents

Methods for treating cardiovascular conditions and methods of increasing the efficiency of cardiac metabolism Download PDF

Info

Publication number
AU2022376557A1
AU2022376557A1 AU2022376557A AU2022376557A AU2022376557A1 AU 2022376557 A1 AU2022376557 A1 AU 2022376557A1 AU 2022376557 A AU2022376557 A AU 2022376557A AU 2022376557 A AU2022376557 A AU 2022376557A AU 2022376557 A1 AU2022376557 A1 AU 2022376557A1
Authority
AU
Australia
Prior art keywords
imb
dose
subjects
compound
trimetazidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022376557A
Other languages
English (en)
Inventor
Paul Chamberlin
Jaikrishna Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imbria Pharmaceuticals Inc
Original Assignee
Imbria Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imbria Pharmaceuticals Inc filed Critical Imbria Pharmaceuticals Inc
Publication of AU2022376557A1 publication Critical patent/AU2022376557A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2022376557A 2021-11-01 2022-10-31 Methods for treating cardiovascular conditions and methods of increasing the efficiency of cardiac metabolism Pending AU2022376557A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163274389P 2021-11-01 2021-11-01
US63/274,389 2021-11-01
PCT/US2022/048401 WO2023076665A1 (en) 2021-11-01 2022-10-31 Methods for treating cardiovascular conditions and methods of increasing the efficiency of cardiac metabolism

Publications (1)

Publication Number Publication Date
AU2022376557A1 true AU2022376557A1 (en) 2024-05-02

Family

ID=86158627

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022376557A Pending AU2022376557A1 (en) 2021-11-01 2022-10-31 Methods for treating cardiovascular conditions and methods of increasing the efficiency of cardiac metabolism

Country Status (9)

Country Link
US (1) US20250235447A1 (https=)
EP (1) EP4426301A4 (https=)
JP (1) JP2024540172A (https=)
KR (1) KR20240095326A (https=)
CN (1) CN118647381A (https=)
AU (1) AU2022376557A1 (https=)
CA (1) CA3236328A1 (https=)
IL (1) IL312523A (https=)
WO (1) WO2023076665A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025054580A1 (en) * 2023-09-08 2025-03-13 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for increasing myocardial capillary formation, reducing left ventricular hypertrophy and/or reducing ventricular dysfunction

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL283725B2 (en) * 2017-06-20 2024-04-01 Imbria Pharmaceuticals Inc Compositions and methods for increasing efficiency of cardiac metabolism
TWI683808B (zh) * 2017-07-18 2020-02-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有胺或(硫)醯胺之lxr調節劑
EP3976103A4 (en) * 2019-05-31 2023-06-28 Imbria Pharmaceuticals, Inc. Methods of altering cardiac remodeling using compounds that promote glucose oxidation

Also Published As

Publication number Publication date
US20250235447A1 (en) 2025-07-24
WO2023076665A1 (en) 2023-05-04
EP4426301A1 (en) 2024-09-11
JP2024540172A (ja) 2024-10-31
CN118647381A (zh) 2024-09-13
CA3236328A1 (en) 2023-05-04
KR20240095326A (ko) 2024-06-25
IL312523A (en) 2024-07-01
EP4426301A4 (en) 2025-09-24

Similar Documents

Publication Publication Date Title
US20250221986A1 (en) Methods of treating kidney conditions using modified forms of trimetazidine
WO2014005013A2 (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US20230210845A1 (en) Dosing methods for treatment of cardiovascular conditions
US20250235447A1 (en) Methods for treating cardiovascular conditions and methods of increasing the efficiency of cardiac metabolism
Karamat et al. The acute effect of beta‐guanidinopropionic acid versus creatine or placebo in healthy men (ABC‐Trial): a randomized controlled first‐in‐human trial
US20210401833A1 (en) Modified release formulations of modified forms of trimetazidine
EP4171232A1 (en) Modified release formulations of modified forms of trimetazidine
Dwivedi et al. Beta-thalassemia, hyperlipoproteinemia (a), and metabolic syndrome: its low-cost holistic therapy
CA2304899C (en) New use of selective serotonin reuptake inhibitors for treatment of human patients with chest pain of non-cardiac origin or with gastro-esophageal reflux disease
US20210401834A1 (en) Modified release formulations of modified forms of trimetazidine
Tablets et al. PrJAMP Pioglitazone
Agent Pr PRO-PIOGLITAZONE
Extremera et al. Clinical Trials on Diabetes Mellitus
Tablets et al. Pr ACT PIOGLITAZONE
Agent Pr AURO-PIOGLITAZONE
Agent PrACH-Pioglitazone
Agent PrRAN™-PIOGLITAZONE
Agent KOMBOGLYZE®
Standard et al. PrACCEL PIOGLITAZONE
Agent PrVAN-Pioglitazone
Hydrochloride et al. PrMYLAN-PIOGLITAZONE
Vibhute A Study on Influence of Diltiazem on Oral Antidiabetic Agents in Experimental Animals
Agent PrJamp-Pioglitazone
Agent PrSANDOZ PIOGLITAZONE
Tablets et al. RAN-Pioglitazone